Merck & Co Inc

MRK has completed a terminal Blow-Off Top reversal in a Stage 3 distribution phase, rejecting former highs on heavy volume and confirming supply dominance with weakening relative strength. Short EMAs have flattened and are acting as resistance, and the pattern marks unsustainable buying pressure. The medium-term bias is now bearish, and the recent rejection at the upper resistance zone provides a timely setup for a sell entry. Execute sell now into that resistance area on the observed rejection.

• ↑2026 revenue guided to $65.8–67B (1–3% growth)
• ↑Keytruda sales rose 8% YoY to $8B; oncology demand strong
• ↓Keytruda patent expires 2028, risking ~50% of revenues